Biotech Values

[10nisman]

GENR... For whom ever still cares about GENR(I do not).

http://biz.yahoo.com/prnews/061016/phm022.html?.v=65

Press Release Source: Genaera Corporation

Genaera Presents New EVIZON(TM) Safety Data at the Angiogenesis Foundation 4th Annual International Conference
Monday October 16, 12:33 pm ET

PLYMOUTH MEETING, Pa., Oct. 16 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR - News) today presented new safety data on EVIZON(TM) (squalamine lactate) for the treatment of wet age-related macular degeneration (AMD). The data was presented at the Angiogenesis Foundation 4th Annual International Conference being held October 16-17, 2006 at the Sheraton Boston Hotel in Boston, Massachusetts. This data will also be presented by Jack Armstrong, President and CEO of Genaera, at the 2006 BIO InvestorForum being held on October 17-19, 2006 at the Palace Hotel in San Francisco, California.

Dr. Andrew Albright, a Genaera scientist, presented data from recent experiments on the effects of EVIZON on endothelial cell nitric oxide synthase (eNOS), an enzyme involved in maintaining normal blood pressure. Inhibition of eNOS activity is a side-effect of anti-VEGF (vascular endothelial growth factor) drugs, such as Avastin® (bevacizumab), and may be a mechanism that contributes to the hypertension and cardiovascular events seen in patients receiving such drugs. Dr. Albright's work demonstrates that EVIZON does not inhibit VEGF-induced eNOS activity in vitro. In addition, he presented data from 124 patients receiving EVIZON therapy for the treatment of wet AMD in Phase 2 clinical trials showing no clinically significant increase in systolic or diastolic blood pressure.

"This evidence that EVIZON does not inhibit eNOS helps to explain our clinical observations that EVIZON therapy is not associated with hypertension, unlike other anti-angiogenic agents, and suggests it may provide a wider margin of cardiovascular safety," said Michael McLane, Vice President, Non- clinical Development at Genaera Corporation. "Because most anti-angiogenic therapies that inhibit all VEGF pathways also inhibit the beneficial effects of eNOS, these findings underscore the fact that EVIZON exerts activity through specific anti-angiogenic and inflammatory signaling pathways, making it a truly novel member of this class."

To view the data presented at the Angiogenesis Foundation 4th Annual International Conference or the presentation being given at the 2006 BIO InvestorForum, please visit the Company's website at http://www.geneara.com.